Unfortunately, their size is limited--too limited to hold the RP1L1 gene. Therefore, a non-viral approach would need to be developed for gene therapy to treat OMD. Since RP1 has the same size problem, a gene therapy for RP could have a spillover effect for OMD. A stem-cell approach might entail taking stem cells from the patient, editing the mutation with CRISR, and inserting the stem cells in the eye. However, as of 2014, researchers did not yet know if retinal stem cell surgery would work. Prevalence
Prevalence is unknown, but seems to be elevated in Asian populations, given that most OMD studies are of Japanese and Korean subjects. Given that Stargardts, the most common macular dystrophy, has a prevalence of 1 in 10,000 in the US,  the prevalence of OMD is likely well below 1 in 100,000. == References ==
(poly-L-lactic acid))..
More recently, two published medical journals appear to show Hyaluronidase injections (Hyaluronidase is an enzyme used to dissolve hyaluronic acid which is a component of our skin that contributes to its thickness) as a possible treatment with promising results. See also
Skin lesion
List of cutaneous conditions

References
Notes

Bibliography

Nguyen NQ (October 2003). "Cutis verticis gyrata". Dermatol. Online J. 9 (4): 32. doi:10.5070/D31DP6W6KS. PMID 14594605. == External links ==